Cite

HARVARD Citation

    He, A. et al. (2019). First‐in‐Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer. Oncologist. pp. e930-e942. [Online]. 
  
Back to record